Polaryx Therapeutics, Inc.
PLYXNasdaq
$2.28
↓ -1.3%Jul 17 close · end-of-day
Price
1Y↓ -93.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$103.6M
Enterprise Value
$100.5M
P/E
—
P/S
—
P/B
41.6
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$9.0M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-361.1%
ROIC
—
Debt / Equity
—
Net Cash
$3.1M
Return 1Y
—
Company profile
We are a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”). Our principal executive offices are located in Paramus, New Jersey.
- CEO
- Alex Yang
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 11
- Headquarters
- New Jersey
- Website
- polaryx.com
Management & directors
- Yang Alex Keun MoChief Executive Officer
- Landis G. MichaelChief Financial Officer
Roles derived from SEC Form 4 filings.
Earnings
PLYX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.05↓ -54.5%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2024 | FY2025 |
|---|---|---|
| Revenue | — | — |
| Gross profit | — | — |
| Operating income | -$4.4M | -$7.8M |
| Net income | -$30.4M | -$9.0M |
| Diluted EPS | -$0.89 | -$0.20 |
| Operating cash flow | -$2.6M | -$3.9M |
| Free cash flow | — | — |
| Gross margin | — | — |
| Operating margin | — | — |
| Net margin | — | — |
| Line item | Q1 '25 | Q1 '26 |
|---|---|---|
| Revenue | — | — |
| Gross profit | — | — |
| Operating income | -$5.1M | -$2.0M |
| Net income | -$5.1M | -$2.5M |
| Diluted EPS | -$0.11 | -$0.05 |
| Operating cash flow | -$709,000.00 | -$2.1M |
| Free cash flow | — | — |
| Gross margin | — | — |
| Operating margin | — | — |
| Net margin | — | — |
Company news
May 14, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-05-27 | Yang Alex Keun Mo· Chief Executive Officer | Buy | 88,453 | $4.07 | $360,003.71 | filing |
| 2026-02-18 | Landis G. Michael· Chief Financial Officer | Buy | 2,867 | $2.79 | $7,990.62 | filing |
Latest 2 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.